Pipeline & Platform
Acelot is advancing a pipeline of novel small-molecule therapies for diseases with limited treatment options. Our work is powered by Resolute, an integrated drug-discovery platform that combines advanced AI-driven computational tools with deep biological insight to tackle complex protein targets that have historically been difficult to drug.
* Acelot is pursuing targets that have demonstrated potential applicability in a range of neurodegenerative diseases, including TDP-43 positive fronto-temporal dementia, Alzheimer's disease (AD), inclusion body myositis, multiple system atrophy, and dementia with Lewy bodies.
ACE-2223
Our lead candidate is ACE-2223, a small molecule specifically designed to target misfolded TDP-43 and restore its healthy form and function. By addressing the root cause of ALS pathology, ACE-2223 has the potential to slow or halt disease progression where no approved therapies currently exist.
Resolute Platform
Resolute is an integrated drug-discovery platform that creates small molecule drug candidates for clinical development. By combining computational biology analysis methods, molecular data sciences, cutting edge structural modeling techniques, and biophysical dynamics, Resolute allows our scientists to engage in the toughest scientific challenges of our age in therapeutic drug discovery.
MOLECULAR DATA SCIENCES
Supports hit finding, hit to lead & lead-optimizations stages of the medicinal chemistry pipeline.
STRUCTURE
Rapid exploration of molecular binding environments to understand on-target structure activity relationships & off-target optimization strategies.
DYNAMICS
Understanding protein-ligand conformational interactions at the molecular level, enabling immersive design & rationalization.
BIOLOGY
Target/disease profiles from multi-omics integration & pathway analysis help us identify opportunities for small molecule drug development.